Darunavir/cobicistat

Saka Wikipédia Jawa, bauwarna mardika basa Jawa
Loncat ke navigasi Loncat ke pencarian
Kombinasi
Darunavir HIV protease inhibitor
Cobicistat Cytochrome P450 (CYP3A) inhibitor
Data klinis
Jeneng dagang Rezolsta, Prezcobix
AHFS/Drugs.com Professional Drug Facts
Data lisènsi US Daily Med:link
Kat. kehamilan B2(AU) ?(US)
Status hukum -only (US)
Rute By mouth
Pangenal
Nomor CAS 206361-99-1 ☒N
Kode ATC J05AR14
PubChem CID 57327017
UNII YO603Y8113Cithakan:Fdacite
KEGG D10832

Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is an antiretroviral medication used to treat and prevent HIV/AIDS.[1] It is a fixed dose combination drug containing 800 mg of darunavir and 150 mg of cobicistat.[1][2][3][1] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.[3][1]

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.[4][5][6][1][7]

Rujukan[besut | besut sumber]

  1. a b c d e "Prezcobix- darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 6 June 2019. Dijupuk 20 February 2020. 
  2. "Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services. 
  3. a b "Darunavir and Cobicistat (Professional Patient Advice)". Drugs.com. 16 September 2019. Dijupuk 19 February 2020. 
  4. "Rezolsta EPAR". European Medicines Agency (EMA). Dijupuk 4 April 2020. 
  5. "Antiretroviral drugs used in the treatment of HIV infection". U.S. Food and Drug Administration (FDA). 12 April 2018. Dijupuk 19 February 2020. 
  6. "Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. January 30, 2015. 
  7. "Prezcobix (darunavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 June 2016. Dijupuk 4 April 2020. 

Pranala jaba[besut | besut sumber]

Cithakan:HIVpharm